Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03831243
Other study ID # CTOR18072GZA
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 9, 2019
Est. completion date October 26, 2023

Study information

Verified date March 2022
Source Cancer Research Antwerp
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase III randomized-controlled, single-blind study comparing the standard schedule for antalgic radiotherapy of a single fraction of 8.0 Gy delivered through three-dimensional conformal radiotherapy (3D-CRT) to a single fraction of 20.0 Gy delivered through stereotactic body radiotherapy (SBRT). The primary aim of this trial is to double the complete response rate. Secondary aims are to compare general response rates, duration of pain response, acute and late toxicity, HRQoL through patient-reported outcome measures (PROMs), pain flare, and re-irradiation need.


Recruitment information / eligibility

Status Completed
Enrollment 126
Est. completion date October 26, 2023
Est. primary completion date October 26, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed malignancy. - Pain score = 2 on a scale from 0 to 10. - Radiological or (bone) scintigraphic evidence of bone metastasis at the site of pain. - Lesions = 5cm in largest diameter. - Per lesion no more than 3 consecutive spine segments involved with one unaffected vertebral body above and below. - No more than 3 painful lesions needing treatment. - Life expectancy estimated at > 3 months. - Patients who have received the information sheet and signed the informed consent form. - Patients must be willing to comply with scheduled visits, treatment plan, and other study procedures. - Patients with a public and/or private health insurance coverage. Exclusion Criteria: - Myeloma. - Bone metastasis in previously irradiated sites. - Previous radioisotope treatment for bone metastases. - Complicated bone metastasis, i.e. impending and/or existing pathological fracture, spinal cord compression or cauda equina compression [16]. - Patients with significantly altered mental status or with psychological, familial, sociological or geographical condition potential hampering compliance with the study. - Individual deprived of liberty or placed under guardianship.

Study Design


Intervention

Radiation:
Stereotactic body radiotherapy
Treatment will be prescribed to the periphery of the target, i.e. 80% of the dose should cover 95% of the PTV. The organ at risk (OAR) dose constraints will be in accordance with the recommendations from the report of the American Association of Physicists in Medicine (AAPM) task group 101. Image-guidance will consist of cone-beam CT in combination with 6 degrees of freedom corrections using robotic couch.
3D-conformal radiotherapy
In the standard setting, 95% of the PTV should receive 95% of the prescribed dose while near maximum dose (Dnear-max) in the PTV should not exceed 107%. Image-guidance will consist of portal images showing the relevant bony anatomy.

Locations

Country Name City State
Belgium Radiotherapy department, GZA Hospitals Wilrijk Antwerp

Sponsors (1)

Lead Sponsor Collaborator
Cancer Research Antwerp

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain response Pain response at the treated index site at 1 month after radiotherapy (RT), as defined by the consensus statement. 4 weeks after RT visit
Secondary Incidence of pain flare Number of participants with increase in pain score of 2 or more above baseline at the treated site with stable OMED, or an increase of 25% or more in OMED compared with baseline with the pain score stable or 1 point above baseline 24-48 hours after radiotherapy
Secondary Duration of pain response Time until pain progression (defined as an increase in pain score of 2 or more above baseline at the treated site with stable daily oral morphine equivalent, or an increase of 25% or more in daily oral morphine equivalent (OMED) compared with baseline with the pain score stable or 1 point above baseline) 2 years after radiotherapy
Secondary Re-irradiation need Need for re-irradiation of the treated lesion 2 years after radiotherapy
Secondary Acute toxicity Measured with CTCAE version 5.0 Measured with CTCAE version 5.0 3 months after radiotherapy
Secondary Late toxicity Measured with CTCAE version 5.0 Measured with CTCAE version 5.0 2 years after radiotherapy
Secondary Impact of treatment on Quality of Life: EORTC quality of life questionnaire (QLQ) BM22 Using the EORTC quality of life questionnaire for Bone Metastases (QLQ BM22) to measure impact of bone metastases on QoL [min score 0 - max score 100]. A high score represents a high level of symptomatology. The score is calculated by applying a linear transformation on the scores to each answer of the 22 question-long questionnaire (cfr. EORTC mannual). 2 years after radiotherapy
Secondary Number of Subsequent Serious Skeletal events Incidence of symptomatic pathologic fractures, radiation or surgery to bone, and spinal cord compression. 2 years after radiotherapy
See also
  Status Clinical Trial Phase
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Active, not recruiting NCT03775980 - CIRSE Emprint Microwave Ablation Registry
Completed NCT01114958 - Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases Phase 1
Terminated NCT03986593 - Cryoablation of Bone Metastases From Endocrine Tumors N/A
Active, not recruiting NCT04458259 - Study of PF-07265807 in Participants With Metastatic Solid Tumors. Phase 1
Completed NCT01218542 - Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc N/A
Not yet recruiting NCT03175146 - A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely N/A
Active, not recruiting NCT02395224 - A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway
Completed NCT02374411 - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients N/A
Recruiting NCT01960829 - Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study Phase 2
Terminated NCT01846429 - Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Phase 1
Completed NCT01933789 - Improving Communication About Serious Illness N/A
Recruiting NCT01564810 - Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer Phase 4
Completed NCT00375245 - Rapamycin With Grapefruit Juice for Advanced Malignancies Phase 1
Completed NCT00232726 - Clinical Study of Previously Untreated Patients With Malignant Melanoma Phase 2
Completed NCT00207116 - An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma Phase 1
Completed NCT00172003 - Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis Phase 4
Completed NCT00207103 - MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors Phase 1